|
1
|
Xing M: Molecular pathogenesis and
mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fagin JA and Wells SA Jr: Biologic and
clinical perspectives on thyroid cancer. N Engl J Med.
375:1054–1067. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Durante C, Haddy N, Baudin E, Leboulleux
S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De
Vathaire F and Schlumberger M: Long-term outcome of 444 patients
with distant metastases from papillary and follicular thyroid
carcinoma: Benefits and limits of radioiodine therapy. J Clin
Endocrinol Metab. 91:2892–2899. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Song HJ, Qiu ZL, Shen CT, Wei WJ and Luo
QY: Pulmonary metastases in differentiated thyroid cancer: Efficacy
of radioiodine therapy and prognostic factors. Eur J Endocrinol.
173:399–408. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brose MS, Nutting CM, Jarzab B, Elisei R,
Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R,
Shong YK, et al: Sorafenib in radioactive iodine-refractory,
locally advanced or metastatic differentiated thyroid cancer: A
randomised, double-blind, phase 3 trial. Lancet. 384:319–328. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pacini F, Castagna MG, Brilli L and
Pentheroudakis G; ESMO Guidelines Working Group, : Thyroid cancer:
ESMO clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 23 (Suppl 7):vii110–vii119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Romesser PB, Sherman EJ, Shaha AR, Lian M,
Wong RJ, Sabra M, Rao SS, Fagin JA, Tuttle RM and Lee NY: External
beam radiotherapy with or without concurrent chemotherapy in
advanced or recurrent non-anaplastic non-medullary thyroid cancer.
J Surg Oncol. 110:375–382. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schlumberger M, Tahara M, Wirth LJ,
Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff
AO, et al: Lenvatinib versus placebo in radioiodine-refractory
thyroid cancer. N Engl J Med. 372:621–630. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de la Fouchardière C, Decaussin-Petrucci
M, Berthiller J, Descotes F, Lopez J, Lifante JC, Peix JL, Giraudet
AL, Delahaye A, Masson S, et al: Predictive factors of outcome in
poorly differentiated thyroid carcinomas. Eur J Cancer. 92:40–47.
2018. View Article : Google Scholar
|
|
10
|
Zheng L, Wang G, Guo W, Pan D, Xie L, He
S, Luo C, Li H, Ran Y, Wu S, et al: NIS and epithelial-mesenchymal
transition marker expression of circulating tumor cells for
predicting and monitoring the radioactive iodine-131 therapy effect
in differentiated thyroid cancers. Mol Biol Rep. 46:4201–4212.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sollini M, di Tommaso L, Kirienko M,
Piombo C, Erreni M, Lania AG, Erba PA, Antunovic L and Chiti A:
PSMA expression level predicts differentiated thyroid cancer
aggressiveness and patient outcome. EJNMMI Res. 9:932019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Song E, Kim M, Kim EY, Kim BH, Shin DY,
Kang HC, Ahn BC, Kim WB, Shong YK, Jeon MJ and Lim DJ: Lenvatinib
for radioactive iodine-refractory differentiated thyroid carcinoma
and candidate biomarkers associated with survival: A multicenter
study in Korea. Thyroid. 30:732–738. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang C, Zhang X, Li H, Li X and Lin Y:
Quantitative thyroglobulin response to radioactive iodine treatment
in predicting radioactive iodine-refractory thyroid cancer with
pulmonary metastasis. PLoS One. 12:e01796642017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Giovanella L, Castellana M and Trimboli P:
Unstimulated high-sensitive thyroglobulin is a powerful prognostic
predictor in patients with thyroid cancer. Clin Chem Lab Med.
58:130–137. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tuttle RM, Haugen B and Perrier ND:
Updated American joint committee on cancer/tumor-node-metastasis
staging system for differentiated and anaplastic thyroid cancer
(eighth edition): What changed and why? Thyroid. 27:751–756. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eijkelenboom A, Kamping EJ, Kastner-van
Raaij AW, Hendriks-Cornelissen SJ, Neveling K, Kuiper RP, Hoischen
A, Nelen MR, Ligtenberg MJ and Tops BB: Reliable next-generation
sequencing of formalin-fixed, paraffin-embedded tissue using single
molecule tags. J Mol Diagn. 18:851–863. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cancer Genome Atlas Research Network, .
Integrated genomic characterization of papillary thyroid carcinoma.
Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jin L, Chen E, Dong S, Cai Y, Zhang X,
Zhou Y, Zeng R, Yang F, Pan C, Liu Y, et al: BRAF and TERT promoter
mutations in the aggressiveness of papillary thyroid carcinoma: A
study of 653 patients. Oncotarget. 7:18346–18355. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xing M, Liu R, Liu X, Murugan AK, Zhu G,
Zeiger MA, Pai S and Bishop J: BRAF V600E and TERT promoter
mutations cooperatively identify the most aggressive papillary
thyroid cancer with highest recurrence. J Clin Oncol. 32:2718–2726.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Baral K and Rotwein P: The insulin-like
growth factor 2 gene in mammals: Organizational complexity within a
conserved locus. PLoS One. 14:e02191552019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bowers LW, Rossi EL, O'Flanagan CH,
deGraffenried LA and Hursting SD: The role of the insulin/IGF
system in cancer: Lessons learned from clinical trials and the
energy balance-cancer link. Front Endocrinol (Lausanne). 6:772015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brouwer-Visser J and Huang GS: IGF2
signaling and regulation in cancer. Cytokine Growth Factor Rev.
26:371–377. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Djiogue S, Nwabo Kamdje AH, Vecchio L,
Kipanyula MJ, Farahna M, Aldebasi Y and Seke Etet PF: Insulin
resistance and cancer: The role of insulin and IGFs. Endocr Relat
Cancer. 20:R1–R17. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Frasca F, Pandini G, Scalia P, Sciacca L,
Mineo R, Costantino A, Goldfine ID, Belfiore A and Vigneri R:
Insulin receptor isoform A, a newly recognized, high-affinity
insulin-like growth factor II receptor in fetal and cancer cells.
Mol Cell Biol. 19:3278–3288. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livingstone C: IGF2 and cancer. Endocr
Relat Cancer. 20:R321–R339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Manabe T, Yasuda H, Terai H, Kagiwada H,
Hamamoto J, Ebisudani T, Kobayashi K, Masuzawa K, Ikemura S, Kawada
I, et al: IGF2 autocrine-mediated IGF1R activation is a clinically
relevant mechanism of osimertinib resistance in lung cancer. Mol
Cancer Res. 18:549–559. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shimizu T, Sugihara E, Yamaguchi-Iwai S,
Tamaki S, Koyama Y, Kamel W, Ueki A, Ishikawa T, Chiyoda T, Osuka
S, et al: IGF2 preserves osteosarcoma cell survival by creating an
autophagic state of dormancy that protects cells against
chemotherapeutic stress. Cancer Res. 74:6531–6541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Steigen SE, Schaeffer DF, West RB and
Nielsen TO: Expression of insulin-like growth factor 2 in
mesenchymal neoplasms. Mod Pathol. 22:914–921. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kasprzak A and Adamek A: Insulin-like
growth factor 2 (IGF2) signaling in colorectal cancer-from basic
research to potential clinical applications. Int J Mol Sci.
20:49152019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sanderson MP, Hofmann MH, Garin-Chesa P,
Schweifer N, Wernitznig A, Fischer S, Jeschko A, Meyer R, Moll J,
Pecina T, et al: The IGF1R/INSR inhibitor BI 885578 selectively
inhibits growth of IGF2-overexpressing colorectal cancer tumors and
potentiates the efficacy of anti-VEGF therapy. Mol Cancer Ther.
16:2223–2233. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Unger C, Kramer N, Unterleuthner D,
Scherzer M, Burian A, Rudisch A, Stadler M, Schlederer M, Lenhardt
D, Riedl A, et al: Stromal-derived IGF2 promotes colon cancer
progression via paracrine and autocrine mechanisms. Oncogene.
36:5341–5355. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sciacca L, Costantino A, Pandini G, Mineo
R, Frasca F, Scalia P, Sbraccia P, Goldfine ID, Vigneri R and
Belfiore A: Insulin receptor activation by IGF-II in breast
cancers: Evidence for a new autocrine/paracrine mechanism.
Oncogene. 18:2471–2479. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tominaga K, Shimamura T, Kimura N,
Murayama T, Matsubara D, Kanauchi H, Niida A, Shimizu S, Nishioka
K, Tsuji EI, et al: Addiction to the IGF2-ID1-IGF2 circuit for
maintenance of the breast cancer stem-like cells. Oncogene.
36:1276–1286. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Q, Shen Y, Ye B, Hu H, Fan C, Wang T,
Zheng Y, Lv J, Ma Y and Xiang M: Gene expression differences
between thyroid carcinoma, thyroid adenoma and normal thyroid
tissue. Oncol Rep. 40:3359–3369. 2018.PubMed/NCBI
|
|
35
|
Malaguarnera R, Frasca F, Garozzo A, Giani
F, Pandini G, Vella V, Vigneri R and Belfiore A: Insulin receptor
isoforms and insulin-like growth factor receptor in human
follicular cell precursors from papillary thyroid cancer and normal
thyroid. J Clin Endocrinol Metab. 96:766–774. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vella V and Malaguarnera R: The emerging
role of insulin receptor isoforms in thyroid cancer: Clinical
implications and new perspectives. Int J Mol Sci. 19:38142018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vella V, Nicolosi ML, Cantafio P,
Massimino M, Lappano R, Vigneri P, Ciuni R, Gangemi P, Morrione A,
Malaguarnera R and Belfiore A: DDR1 regulates thyroid cancer cell
differentiation via IGF-2/IR-A autocrine signaling loop. Endocr
Relat Cancer. 26:197–214. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vella V, Pandini G, Sciacca L, Mineo R,
Vigneri R, Pezzino V and Belfiore A: A novel autocrine loop
involving IGF-II and the insulin receptor isoform-A stimulates
growth of thyroid cancer. J Clin Endocrinol Metab. 87:245–254.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Y, Gan G, Wang B, Wu J, Cao Y, Zhu D,
Xu Y, Wang X, Han H, Li X, et al: Cancer-associated fibroblasts
promote irradiated cancer cell recovery through autophagy.
EBioMedicine. 17:45–56. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang Q, Yang J, Bai J and Ren J: Reverse
of non-small cell lung cancer drug resistance induced by
cancer-associated fibroblasts via a paracrine pathway. Cancer Sci.
109:944–955. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li T, Wang J, Liu P, Chi J, Yan H, Lei L,
Li Z, Yang B and Wang X: Insulin-like growth factor 2 axis supports
the serum-independent growth of malignant rhabdoid tumor and is
activated by microenvironment stress. Oncotarget. 8:47269–47283.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
El Tayebi HM, Salah W, El Sayed IH, Salam
EM, Zekri AR, Zayed N, Salem ES, Esmat G and Abdelaziz AI:
Expression of insulin-like growth factor-II, matrix
metalloproteinases, and their tissue inhibitors as predictive
markers in the peripheral blood of HCC patients. Biomarkers.
16:346–354. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Peters G, Gongoll S, Langner C, Mengel M,
Piso P, Klempnauer J, Rüschoff J, Kreipe H and von Wasielewski R:
IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and
predictive markers in colorectal-cancer. Virchows Arch.
443:139–145. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Van Arsdale AR, Arend RC, Cossio MJ,
Erickson BK, Wang Y, Doo DW, Leath CA, Goldberg GL and Huang GS:
Insulin-like growth factor 2: A poor prognostic biomarker linked to
racial disparity in women with uterine carcinosarcoma. Cancer Med.
7:616–625. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ewing GP and Goff LW: The insulin-like
growth factor signaling pathway as a target for treatment of
colorectal carcinoma. Clin Colorectal Cancer. 9:219–223. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Buck E, Gokhale PC, Koujak S, Brown E,
Eyzaguirre A, Tao N, Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild
R, et al: Compensatory insulin receptor (IR) activation on
inhibition of insulin-like growth factor-1 receptor (IGF-1R):
Rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther.
9:2652–2664. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Malaguarnera R and Belfiore A: The insulin
receptor: A new target for cancer therapy. Front Endocrinol
(Lausanne). 2:932011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mulvihill MJ, Cooke A, Rosenfeld-Franklin
M, Buck E, Foreman K, Landfair D, O'Connor M, Pirritt C, Sun Y, Yao
Y, et al: Discovery of OSI-906: A selective and orally efficacious
dual inhibitor of the IGF-1 receptor and insulin receptor. Future
Med Chem. 1:1153–1171. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Puzanov I, Lindsay CR, Goff L, Sosman J,
Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A,
et al: A phase I study of continuous oral dosing of OSI-906, a dual
inhibitor of insulin-like growth factor-1 and insulin receptors, in
patients with advanced solid tumors. Clin Cancer Res. 21:701–711.
2015. View Article : Google Scholar : PubMed/NCBI
|
